Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Infection and Chemotherapy
Published in: Journal of Infection and Chemotherapy 5/2010

01-10-2010 | Note

Clinical features of Proteus mirabilis pneumonia

Authors: Niro Okimoto, Toshikiyo Hayashi, Mitsunori Ishiga, Fumiyo Nanba, Michihiro Kishimoto, Shinichi Yagi, Takeyuki Kurihara, Naoko Asaoka, Sadao Tamada

Published in: Journal of Infection and Chemotherapy | Issue 5/2010

Login to get access

Abstract

In this study, we clinically reviewed 13 patients with Proteus mirabilis pneumonia who were admitted for treatment to Kawasaki Medical School Kawasaki Hospital, Okayama, Japan, between April 2006 and July 2009. Clinical features were retrospectively reviewed. Results showed that: (1) hospital-acquired pneumonia occurred in elderly patients with underlying diseases such as cerebrovascular disease; (2) some patients had complications of urinary tract infection due to P. mirabilis; (3) preadministration of antibacterial agents did not become a risk factor; (4) resistance for levofloxacin (LVFX) was observed; (5) prognosis was comparatively good (effective rate 84.7%).
Literature
1.
Watanakakunakorn C, Perni SC. Proteus mirabilis bacteremia: a review of 176 cases during 1980–1992. Scand J Infect Dis. 1994;26:361–7.CrossRef
2.
The Committee for the JRS Guidelines in Management of Respiratory Infections. The JRS guidelines for the management of hospital-acquired pneumonia in adults. Kyorinsya, Tokyo, 2008, pp 1–3.
3.
Lysy J, Werczberger A, Globus M, Chowers I. Pneumatocele formation in a patient with Proteus mirabilis. Postgrad Med J. 1985;61:255–7.CrossRefPubMed
4.
Oventchin PV, Tsyganenko A. Antibiotic response of Proteus strains isolated from clinical material of different types. Antibiotiki. 1984;29:272–5.
5.
Greenberg RN, Reilly PM, Luppen KL, Bollinger M, McMillian R. Aztreonam therapy for gram-negative pneumonia. Am J Med. 1985;78:31–3.CrossRefPubMed
6.
Okimoto N, Ishiga M, Nanba F, Kibayashi T, Kishimoto M, Kuruhara T, et al. Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly. JJRS. 2009;47:553–7.
7.
The Committee for Clinical Evaluation of Antibiotics in Japanese Chemotherapy Society. Clinical evaluation of new antibiotics in respiratory infections. Jpn J Chemother 1997;45:762–78.
Metadata
Title
Clinical features of Proteus mirabilis pneumonia
Authors
Niro Okimoto
Toshikiyo Hayashi
Mitsunori Ishiga
Fumiyo Nanba
Michihiro Kishimoto
Shinichi Yagi
Takeyuki Kurihara
Naoko Asaoka
Sadao Tamada
Publication date
01-10-2010
Publisher
Springer Japan
Published in
Journal of Infection and Chemotherapy / Issue 5/2010
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-010-0059-3

Other articles of this Issue 5/2010

Journal of Infection and Chemotherapy 5/2010 Go to the issue

Original Article

Genotyping of Pseudomonas aeruginosa isolated from cockroaches and human urine

Original Article

Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing

Case Report

Epidural abscess caused by community-associated methicillin-resistant Staphylococcus aureus strain USA300 in Japan

Note

Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay

Note

Spread of the community-acquired methicillin-resistant Staphylococcus aureus USA300 clone among family members in Japan

Review Article

Blood cultures: key elements for best practices and future directions
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits